Last reviewed · How we verify
ACE-232 tablets
At a glance
| Generic name | ACE-232 tablets |
|---|---|
| Sponsor | Acerand Therapeutics (Hong Kong) Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACE-232 tablets CI brief — competitive landscape report
- ACE-232 tablets updates RSS · CI watch RSS
- Acerand Therapeutics (Hong Kong) Limited portfolio CI